Beijing En Zhe Jia Shi Pharmaceutical

Beijing Enzhejiashi Pharmaceutical is a clinical-stage biopharmaceutical company based in China that specializes in the development of innovative treatments for rare metabolic diseases and urinary system disorders. The company's lead candidate, EJ1-001, is a small molecule inhibitor targeting the cystine transporter for the treatment of cystinuria, a genetic condition that causes recurrent kidney stones. Enzhejiashi focuses on addressing significant unmet medical needs in the field of nephrology and metabolic health through targeted small molecule discovery. The company has successfully advanced its primary programs into mid-stage clinical trials in both China and the United States.